Vertex's Next Steps Closely Watched Following Merck-Roche Deal On Victrelis
Executive Summary
All eyes are on Vertex Pharmaceuticals and whether it will change course and seek a marketing partner following the May 17 announcement that Merck and Roche will co-promote Merck’s newly approved hepatitis C drug Victrelis (boceprevir).
You may also be interested in...
From Inflection To Insight: Vertex And Merck’s Dueling HCV Drugs
Welcome to Inflection to Insight, a new series taking a closer look at notable chapters in biopharma history, gleaning learnings to inform current business strategy. This inaugural instalment looks at the rapid rise and fall of two competing drugs for hepatitis C virus, Vertex’s Incivek and Merck & Co’s Victrelis.
Pharmasset Casts Wide Phase III Net With Interferon-Free, Two-Drug Combo
Phase II ELECTRON study yielded 100% cure rate across all arms, including interferon-sparing and interferon-free regimens.
Vertex Out To Significant Early Lead In HCV Protease Inhibitor Competition With Merck
Most market analysts predicted Vertex's protease inhibitor would be a bigger seller than Merck's, but a greater than 10-to-1 disparity in third-quarter net sales is still eye-opening.